SRR934780
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.702
- INTERFERON_GAMMA_RESPONSE+0.623
- ALLOGRAFT_REJECTION+0.490
- G2M_CHECKPOINT+0.451
- MITOTIC_SPINDLE+0.415
- MYC_TARGETS_V1+0.409
- TGF_BETA_SIGNALING+0.406
- UNFOLDED_PROTEIN_RESPONSE+0.396
- IL6_JAK_STAT3_SIGNALING+0.384
- PROTEIN_SECRETION+0.354
Top 10 suppressed
- BILE_ACID_METABOLISM-0.376
- KRAS_SIGNALING_DN-0.356
- MYOGENESIS-0.271
- PANCREAS_BETA_CELLS-0.270
- SPERMATOGENESIS-0.256
- XENOBIOTIC_METABOLISM-0.239
- PEROXISOME-0.202
- ESTROGEN_RESPONSE_LATE-0.198
- OXIDATIVE_PHOSPHORYLATION-0.196
- FATTY_ACID_METABOLISM-0.172
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BF513557-1518-4843-9F62-837B557D4CAB | — | — | 0.921 |
| 2 | MNG1210 | — | — | 0.915 |
| 3 | SRR934956 | — | — | 0.910 |
| 4 | TCGA-83-5908-01A-21R-2287-07 | — | cohortA1 | 0.908 |
| 5 | TCGA-GC-A3RC-01A-11R-A22U-07 | — | — | 0.899 |
| 6 | TCGA-77-A5GH-01A-11R-A27Q-07 | — | cohortSQ1 | 0.899 |
| 7 | TCGA-BT-A3PJ-01A-21R-A220-07 | — | — | 0.896 |
| 8 | 33233781-A799-4610-86FC-C836713D31AA | — | — | 0.896 |
| 9 | TCGA-CR-7373-01A-11R-2016-07 | — | — | 0.891 |
| 10 | SRR934940 | — | — | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.702 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.623 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.490 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.451 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.415 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.409 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.406 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.396 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.384 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.354 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.347 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.341 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.329 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.295 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.275 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |
| COMPLEMENT | 0.252 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.252 | Inavolisib | — uncovered |
| APOPTOSIS | 0.236 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.227 | Inavolisib | — uncovered |